MARKET

VNDA

VNDA

Vanda Pharma
NASDAQ
8.54
+0.41
+5.04%
Pre Market: 7.49 -1.05 -12.30% 08:11 01/08 EST
OPEN
8.10
PREV CLOSE
8.13
HIGH
8.55
LOW
8.06
VOLUME
177.21K
TURNOVER
0
52 WEEK HIGH
9.60
52 WEEK LOW
3.809
MARKET CAP
504.69M
P/E (TTM)
-5.9658
1D
5D
1M
3M
1Y
5Y
1D
Vanda falls as FDA rejects jet lag drug
Seeking Alpha · 4h ago
Vanda Shares Fall Premarket as FDA Again Rejects Hetlioz for Jet Lag
Dow Jones · 4h ago
BUZZ-Vanda falls as US FDA rejects jet lag drug application
Reuters · 4h ago
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application
TipRanks · 4h ago
Vanda Pharmaceuticals down 11% to $7.55 after FDA rejects sNDA for hetlioz
TipRanks · 4h ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 4h ago
Vanda Pharmaceuticals: FDA says sNDA for hetlioz can’t be approved
TipRanks · 4h ago
Vanda Pharma Receives Decision Letter From FDA's CDER Concluding That sNDA For HETLIOZ For Treatment Of Jet Lag Disorder Cannot Be Approved In Its Current Form
Benzinga · 4h ago
More
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Webull offers Vanda Pharmaceuticals Inc. stock information, including NASDAQ: VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.